A quasi-experimental study finds print-based education improves self-care in type 2 diabetes patients in Nigeria, without measuring glycaemic outcomes. PICO summary and commentary.
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A recruitment analysis finds men, Hispanics, and Spanish speakers underenrol at every step of a diabetes exercise trial despite active outreach. PICO summary and commentary.
A 20-week RCT finds empagliflozin improves nerve conduction velocity in diabetic neuropathy but not clinical exam scores, with glycaemic confounding. PICO summary and commentary.
A small unblinded trial finds Huayu Tongluo moxibustion improves cognition and insulin resistance in type 2 diabetes, with high placebo potential. PICO summary and commentary.
The INTE-COMM Lancet trial finds community-based care matches facility care for stable HIV, diabetes, and hypertension in sub-Saharan Africa. PICO summary and expert commentary.
A clamp-based RCT finds metformin does not reduce hepatic insulin resistance in type 1 diabetes, arguing against its use as an insulin-sensitiser. PICO summary and commentary.
The CREDENCE trial demonstrated that canagliflozin reduced the composite of end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death by 30% in patients with type 2 diabetes and albuminuric chronic kidney disease, becoming the first dedicated renal outcomes trial to demonstrate that an SGLT2 inhibitor could substantially slow the progression of diabetic nephropathy.
A sham-controlled trial finds tibial nerve neurodynamic techniques improve neuropathy severity and quality of life in diabetic neuropathy, without changing nerve conduction. PICO summary and commentary.
The DECLARE-TIMI 58 trial demonstrated that dapagliflozin did not reduce 3-point MACE compared with placebo but significantly reduced the composite of cardiovascular death or hospitalisation for heart failure, driven entirely by a 27% reduction in heart failure hospitalisation, in the largest and most broadly representative SGLT2 inhibitor cardiovascular outcomes trial conducted to date.
The FINE-ONE NEJM trial finds finerenone reduces albuminuria in type 1 diabetes and CKD, a surrogate-based extension of its type 2 benefits. PICO summary and commentary.